Advanced BioHealing, Inc., which manufactures and sells Dermagraft, a regenerative skin substitute that treats diabetic foot ulcers, announced terms for its IPO on Thursday. The Westport, CT-based company plans to raise $200 million by offering 13.4 million shares at a price range of $14 to $16. At the mid-point of the proposed range, Advanced BioHealing, Inc. will command a market value of $732 million. Advanced BioHealing, Inc., which was founded in 2004 and booked $161 million in sales for the 12 months ended April 2, 2011, plans to list on the NASDAQ under the symbol ABHB. BofA Merrill Lynch and J.P. Morgan are the lead underwriters on the deal, which is expected to price during the week of May 16.